Linifanib | ABT-869 | VEGFR/PDGFR Inhibitor (GMP) | AmBeed-信号通路专用抑制剂

首页 / / / / Linifanib

利尼伐尼 /Linifanib {[allProObj[0].p_purity_real_show]}

货号：A147574 同义名： ABT-869;AL-39324

Linifanib is a potent ATP-competitive VEGFR/PDGFR inhibitor for KDR, CSF-1R, Flt-1/3 and PDGFRβ with IC50 of 4 nM, 3 nM, 3 nM/4 nM and 66 nM respectively.

Linifanib 化学结构
CAS号：796967-16-3

Linifanib 3D分子结构
CAS号：796967-16-3

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Linifanib 纯度/质量文件产品仅供科研

货号：A147574 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]; • JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]; • BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]; • J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]; • PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]; 更多 >

PDGFR 亚型比较
VEGFR 亚型比较

产品名称	PDGFR ↓ ↑	PDGFRα ↓ ↑	PDGFRβ ↓ ↑	其他靶点	纯度
Tyrphostin A9	+ PDGFR, IC50: 0.5 μM			EGFR	98%
Tyrphostin AG1296					99%+
Motesanib Diphosphate	++ PDGFR, IC50: 84 nM				98%
Pazopanib	++ PDGFR, IC50: 84 nM				99%
Imatinib	+ PDGFR, IC50: 100 nM			c-Kit	98%
Imatinib Mesylate	+ PDGFR, IC50: 100 nM			c-Kit	99%
Sennoside B	✔				99%+
PP121	++++ PDGFR, IC50: 2 nM			mTOR,VEGFR	99%+
Crenolanib		++++ PDGFRα, Kd: 2.1 nM	++++ PDGFRβ, Kd: 3.2 nM		99%+
Masitinib		+ PDGFRα, IC50: 540 nM	+ PDGFRβ, IC50: 800 nM		99%+
Ki8751		++ PDGFRα, IC50: 67 nM		c-Kit	98+%
Tivozanib		++ PDGFRα, IC50: 40 nM	++ PDGFRβ, IC50: 49 nM		99%+
Ponatinib		++++ PDGFRα, IC50: 1.1 nM			98%
Amuvatinib		++ PDGFRα (V561D), IC50: 40 nM			99%+
Axitinib		+++ PDGFRα, IC50: 5.0 nM	++++ PDGFRβ, IC50: 1.6 nM		98%
CP-673451		+++ PDGFRα, IC50: 10 nM	++++ PDGFRβ, IC50: 1 nM		99%+
Telatinib		+++ PDGFRα, IC50: 15 nM		c-Kit	99%+
Nintedanib		++ PDGFRα, IC50: 59 nM	++ PDGFRβ, IC50: 65 nM		99+%
Avapritinib		++++ PDGFRα (D842V), IC50: 0.5 nM			99%+
MK-2461			+++ PDGFRβ, IC50: 22 nM		98%+
Lactate			+++ PDGFRβ, IC50: 27 nM	c-Kit,FLT3	85%
Linifanib			++ PDGFRβ, IC50: 66 nM		99%+
AZD2932			+++ PDGFRβ, IC50: 4 nM	c-Kit	98%
Dovitinib			+++ PDGFRβ, IC50: 27 nM	c-Kit,FLT3	99%+
Sorafenib			++ mPDGFRβ, IC50: 57 nM PDGFRβ, IC50: 57 nM		99%
Sunitinib			++++ PDGFRβ , IC50: 2 nM	FLT3	98%
Orantinib			+++ PDGFRβ, Ki: 8 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	VEGFR1 ↓ ↑	VEGFR2 ↓ ↑	VEGFR3 ↓ ↑	其他靶点	纯度
Motesanib Diphosphate	++++ VEGFR1, IC50: 2 nM	++++ VEGFR2/Flk1, IC50: 3 nM VEGFR2, IC50: 3 nM	+++ VEGFR3, IC50: 6 nM	RET,PDGFR	98%
Tivozanib	++ VEGFR1, IC50: 30 nM	+++ VEGFR2, IC50: 6.5 nM	++ VEGFR3, IC50: 15 nM		99%+
Brivanib	+ VEGFR1, IC50: 380 nM	++ Flk1, IC50: 25 nM VEGFR2, IC50: 25 nM			99%+
Regorafenib	+++ VEGFR1, IC50: 13 nM	+++ VEGFR2, IC50: 4.2 nM	+ VEGFR3, IC50: 46 nM	RET	98%
Pazopanib	+++ VEGFR1, IC50: 10 nM	++ VEGFR2, IC50: 30 nM	+ VEGFR3, IC50: 47 nM	FGFR,c-Kit,PDGFR	99%
Sitravatinib	+++ VEGFR1 (FLT1), IC50: 6 nM	+++ VEGFR2 (KDR), IC50: 5 nM	++++ VEGFR3 (FLT4), IC50: 2 nM		99%+
Foretinib	+++ VEGFR1/FLT1, IC50: 6.8 nM	++++ KDR, IC50: 0.86 nM	++++ VEGFR3/FLT4, IC50: 2.8 nM	Tie-2	99%+
MGCD-265 analog	++++ VEGFR1, IC50: 3 nM	++++ VEGFR2, IC50: 3 nM	++++ VEGFR3, IC50: 4 nM	Tie-2	99%+
Lactate	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	c-Kit,FLT3	85%
AEE788	+ FLT1, IC50: 59 nM	+ KDR, IC50: 77 nM		EGFR	98+%
Linifanib	++++ VEGFR1/FLT1, IC50: 3 nM	++++ VEGFR2/KDR, IC50: 4 nM	+ VEGFR3/FLT4, IC50: 190 nM	FLT3	99%+
Vatalanib 2HCl	+ VEGFR1/FLT1, IC50: 77 nM	++ VEGFR2/KDR, IC50: 37 nM VEGFR2/Flk1, IC50: 270 nM	+ VEGFR3/FLT4, IC50: 660 nM	c-Kit,c-Fms	99%+
Axitinib	++++ VEGFR1/FLT1, IC50: 0.1 nM	++++ VEGFR2/KDR, IC50: 0.2 nM VEGFR2/Flk1, IC50: 0.18 nM			98%
Dovitinib	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	c-Kit,FLT3	99%+
ZM 306416	+ VEGFR1, IC50: 0.33 μM			Src	99%+
KRN-633	+ VEGFR1, IC50: 170 nM	+ VEGFR2, IC50: 160 nM	+ VEGFR3, IC50: 125 nM	c-Kit,BTK	98%
OSI-930	+++ FLT1, IC50: 8 nM	+++ KDR, IC50: 9 nM			99%+
Lenvatinib	++ VEGFR1/FLT1, IC50: 22 nM	++++ VEGFR2/KDR, IC50: 4.0 nM	+++ VEGFR3/FLT4, IC50: 5.2 nM		98%
NVP-BAW2881	+ hVEGFR1, IC50: 820 nM	+++ mVEGF2, IC50: 165 nM hVEGFR2, IC50: 9 nM	+ hVEGFR3, IC50: 420 nM		98%
Cediranib	+++ VEGFR1/FLT1, IC50: 5 nM	++++ VEGFR2/KDR, IC50: 0.5 nM		c-Kit	99%+
Nintedanib	++ VEGFR1, IC50: 34 nM	+++ VEGFR2, IC50: 13 nM	+++ VEGFR3, IC50: 13 nM	FLT3	99+%
BMS-794833		++ VEGFR2, IC50: 15 nM			99%+
SKLB1002		++ VEGFR2, IC50: 32 nM			98%
Cabozantinib S-malate		++++ VEGFR2/KDR, IC50: 0.035 nM			99+%
Ki8751		++++ VEGFR2, IC50: 0.9 nM		c-Kit	98+%
SU 5402		++ VEGFR2, IC50: 20 nM			98%
Rivoceranib Mesylate		++++ VEGFR2, IC50: 1 nM		RET	98+%
Ponatinib		++++ VEGFR2, IC50: 1.5 nM			98%
LY2874455		+++ VEGFR2, IC50: 7 nM			99%+
ZM323881 HCl		++++ VEGFR2, IC50: <2 nM			98%
AZD2932		+++ VEGFR-2, IC50: 8 nM		c-Kit	98%
Cabozantinib		++++ VEGFR2/KDR, IC50: 0.035 nM			98%
Sorafenib		++ VEGFR2/Flk1, IC50: 90 nM VEGFR2, IC50: 90 nM			99%
CYC-116		++ VEGFR2, Ki: 44 nM		FLT3	99%+
Golvatinib		++ VEGFR2, IC50: 16 nM			99%+
Sunitinib		+ VEGFR2 , IC50: 80 nM		FLT3	98%
RAF265		++ VEGFR2, EC50: 30 nM			99%+
PD173074					99%+
BFH772		++++ VEGFR2, IC50: 3 nM			98%
Semaxinib		+ VEGFR2/Flk1, IC50: 1.23 μM			98%
Vandetanib		++ VEGFR2, IC50: 40 nM	+ VEGFR3, IC50: 110 nM	EGFR	98%
SAR131675			++ VEGFR3, IC50: 23 nM		99%+
ENMD-2076		+ VEGFR2/KDR, IC50: 58.2 nM	++ VEGFR3/FLT4, IC50: 15.9 nM	RET,FLT3	98%
Telatinib		+++ VEGFR2, IC50: 6 nM	++++ VEGFR3, IC50: 4 nM	c-Kit	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Linifanib 生物活性

靶点	VEGFR1 VEGFR1/FLT1, IC50:3 nM VEGFR3 VEGFR3/FLT4, IC50:190 nM VEGFR2 VEGFR2/KDR, IC50:4 nM PDGFRβ PDGFRβ, IC50:66 nM
描述	Linifanib is a muti-target inhibitor with IC50 values of 3nM, 3nM, 4nM, 4nM, 14nM and 66nM for VEGFR1, CSF-1R, VEGFR2, FLT3, c-Kit and PDGFRβ(measured by kinase assays), respectively. Linifanib showed in cellular inhibition on ligand-induced phosphorylation of PDGFR-βKDR and CSF-1R with IC50 values of 2nM, 31nM and 10nM, respectively, in 3T3 transfectants, as well as VEGF-induced proliferation with IC50 value of 0.2nM for human endothelial cells^[1]. The in vivo study showed that, consistent with the inhibition of VEGFR and PDGFRβby Linifanib, oral administration of Linifanib at dose of 7.5 and 15mg/kg, BID, significantly inhibited bFGF- and VEGF-induced increases of vessel density in the cornea. Oral treatment with Linifanib at dose ranging in 1.5-12.5mg/kg, BID, could significantly reduce the tumor growth or in several orthotopic tumor models, including MDA-231 and MDA-435LM xenograft mice and rat glioma, or enhance the anti-tumor effect of paclitaxel in the models^[1].
作用机制	Linifanib can bind to the ATP-binding site of CSF-1R.^[2]

Linifanib 细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源
human MOLM13 cells		Cytotoxicity assay	72 h	Cytotoxicity against human MOLM13 cells harboring mutant FLT3 after 72 hrs by MTS assay, GI50=0.037 μM	23618709
human MOLT4 cells		Proliferation assay	72 h	Antiproliferation activity against human MOLT4 after 72 hrs by MTS method, GI50=6.7 μM	21708468
human MV4-11 cells		Proliferation assay	72 h	Antiproliferation activity against FLT3/ITD harboring human MV4-11 cells after 72 hrs by MTS method, GI50=0.04 μM	21708468
mouse 3T3 cells		Function assay		Inhibition of VEGF-induced human KDR phosphorylation in mouse 3T3 cells by ELISA, IC50=0.004 μM	17343372

Linifanib 动物研究

Dose

Mice: 25 mg/kg^[3] (p.o., BID), 1.5 mg/kg - 15 mg/kg^[1] (p.o.)

Administration

p.o.

Pharmacokinetics

Animal	Rats^[4]	Dogs^[4]	Monkeys^[4]
Dose	5 mg/kg (i.v./p.o.)	2.5 mg/kg (i.v./p.o.)	2.5 mg/kg (i.v./p.o.)
Administration	i.v. p.o.	i.v. p.o.	i.v. p.o.
F	27% (p.o.)	47% (p.o.)	10.6% (p.o.)
V_d	1.1 L/kg (i.v.)	1.2 L/kg (i.v.)	2.2 L/kg (i.v.)
T_1/2	3.6 h (i.v.)	2.0 h (i.v.)	3.1 h (i.v.)
AUC	6.8 µg·h/ml (p.o.)	1.5 µg·h/ml (p.o.)	0.6 µg·h/ml (p.o.)
CL	3.3 ml/min·kg (i.v.)	7.2 ml/min·kg (i.v.)	8.2 ml/min·kg (i.v.)

Linifanib 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT03481842	Endometriosis ... 展开 >> Endometriosis Ovary Endometriosis Externa Endometriosis, Rectum 收起 <<	Phase 1 Phase 2	Not yet recruiting	September 30, 2018	Switzerland ... 展开 >> BioGene Pharmaceutical Ltd. Not yet recruiting Basel, Вâlе, Switzerland, 4057 Contact: J. Łanevska, Dr jula.edu@yahoo.com 收起 <<
NCT00707889	Advanced Colorectal Cancer ... 展开 >> Adenocarcinoma of the Colon Adenocarcinoma of the Rectum 收起 <<	Phase 2	Completed	-	-
NCT00716534	Advanced or Metastatic Non-Sma... 展开 >>ll Cell Lung Cancer 收起 <<	Phase 2	Completed	-	-

Linifanib 参考文献

[1]Albert DH, Tapang P, et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2006;5(4):995-1006.

[2]Guo J, Marcotte PA, et al. Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther. 2006;5(4):1007-13.

[3]Jiang F, Albert DH, et al. ABT-869, a multitargeted receptor tyrosine kinase inhibitor, reduces tumor microvascularity and improves vascular wall integrity in preclinical tumor models. J Pharmacol Exp Ther. 2011 Jul;338(1):134-42.

[4]Dai Y, Hartandi K, et al. Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. J Med Chem. 2007 Apr 5;50(7):1584-97. Epub 2007 Mar 8.

Linifanib 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.66mL

0.53mL

0.27mL

13.32mL

2.66mL

1.33mL

26.64mL

5.33mL

2.66mL

Linifanib 技术信息

CAS号	796967-16-3
分子式	C₂₁H₁₈FN₅O
分子量	375.399

别名	ABT-869;AL-39324
运输	蓝冰

存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Inert atmosphere,2-8°C

溶解度

DMSO: 12 mg/mL(31.97 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

5%DMSO+40%PEG 300+5%Tween80+50%water 10 mg/mL

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT03481842	Endometriosis ... 展开 >> Endometriosis Ovary Endometriosis Externa Endometriosis, Rectum 收起 <<	Phase 1 Phase 2	Not yet recruiting	September 30, 2018	Switzerland ... 展开 >> BioGene Pharmaceutical Ltd. Not yet recruiting Basel, Вâlе, Switzerland, 4057 Contact: J. Łanevska, Dr jula.edu@yahoo.com 收起 <<
NCT00707889	Advanced Colorectal Cancer ... 展开 >> Adenocarcinoma of the Colon Adenocarcinoma of the Rectum 收起 <<	Phase 2	Completed	-	-
NCT00716534	Advanced or Metastatic Non-Sma... 展开 >>ll Cell Lung Cancer 收起 <<	Phase 2	Completed	-	-
NCT00718380	Solid Tumor	Phase 1	Completed	-	-
NCT00486538	Advanced Renal Cell Carcinoma	Phase 2	Completed	-	United States, California ... 展开 >> Site Reference ID/Investigator# 7193 Sacramento, California, United States, 95817 United States, District of Columbia Site Reference ID/Investigator# 5243 Washington, District of Columbia, United States, 20010 United States, Illinois Site Reference ID/Investigator# 5384 Chicago, Illinois, United States, 60637 United States, Massachusetts Site Reference ID/Investigator# 11662 Boston, Massachusetts, United States, 02114 Site Reference ID/Investigator# 11663 Boston, Massachusetts, United States, 02114 Site Reference ID/Investigator# 5379 Boston, Massachusetts, United States, 02114 United States, New Hampshire Site Reference ID/Investigator# 5380 Lebanon, New Hampshire, United States, 03756-0001 United States, Pennsylvania Site Reference ID/Investigator# 5249 Philadelphia, Pennsylvania, United States, 19111 Site Reference ID/Investigator# 6278 Philadelphia, Pennsylvania, United States, 19111 Site Reference ID/Investigator# 6269 Pittsburgh, Pennsylvania, United States, 15232 United States, South Carolina Site Reference ID/Investigator# 7300 Charleston, South Carolina, United States, 29425 United States, Texas Site Reference ID/Investigator# 6796 Houston, Texas, United States, 77030-4009 Canada Site Reference ID/Investigator# 6566 Vancouver, Canada, V5Z 4E6 收起 <<
NCT00733187	Advanced Solid Tumors	Phase 1	Completed	-	-
NCT00645177	Metastatic Breast Cancer	Phase 2	Completed	-	United States, California ... 展开 >> Site Reference ID/Investigator# 8352 San Francisco, California, United States, 94115 United States, Illinois Site Reference ID/Investigator# 6920 Harvey, Illinois, United States, 60426 Mexico Site Reference ID/Investigator# 10181 Durango, DGO., Mexico, CP 34000 收起 <<
NCT01009593	Hepatocellular Carcinoma Non-r... 展开 >>esectable Hepatocellular Carcinoma Recurrent Carcinoma, Hepatocellular Liver Diseases Neoplasms by Histologic Type Digestive System Neoplasms Carcinoma Liver Neoplasms Neoplasms Neoplasms by Site Digestive System Diseases Adenocarcinoma Neoplasms, Glandular and Epithelial 收起 <<	Phase 3	Terminated(See termination rea... 展开 >>son in detailed description) 收起 <<	-	-
NCT01225302	Non-Small Cell Lung Cancer	Phase 1	Completed	-	-
NCT01286974	Advanced Solid Tumors	Phase 1	Terminated(Terminated early, S... 展开 >>ponsor Decision) 收起 <<	-	United States, Ohio ... 展开 >> Site Reference ID/Investigator# 40942 Cleveland, Ohio, United States, 44195 Site Reference ID/Investigator# 53663 Cleveland, Ohio, United States, 44195 收起 <<
NCT00517790	Non-Small Cell Lung Cancer (NS... 展开 >>CLC) 收起 <<	Phase 2	Completed	-	-
NCT01365910	Recurrent Colon Cancer ... 展开 >> Recurrent Rectal Cancer Stage IVA Colon Cancer Stage IVA Rectal Cancer Stage IVB Colon Cancer Stage IVB Rectal Cancer 收起 <<	Phase 2	Terminated(Interim analysis de... 展开 >>termined the study did not meet criteria to proceed) 收起 <<	-	United States, Tennessee ... 展开 >> Vanderbilt Cool Springs Franklin, Tennessee, United States, 37067 Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232-6838 收起 <<
NCT01114191	Solid Tumors	Phase 1	Completed	-	United States, Michigan ... 展开 >> Site Reference ID/Investigator# 35784 Detroit, Michigan, United States, 48201 United States, New Hampshire Site Reference ID/Investigator# 36527 Lebanon, New Hampshire, United States, 03756-0001 收起 <<
NCT01413893	Advanced Solid Tumors	Phase 1	Completed	-	-
NCT01365910	-		Terminated(Interim analysis de... 展开 >>termined the study did not meet criteria to proceed) 收起 <<	-	-
NCT01401933	Advanced Solid Tumors	Phase 1	Completed	-	United States, Arizona ... 展开 >> Site Reference ID/Investigator# 49953 Tucson, Arizona, United States, 85724-5024 United States, Wisconsin Site Reference ID/Investigator# 49952 Madison, Wisconsin, United States, 53792 收起 <<
NCT01506934	Advanced or Metastatic Solid T... 展开 >>umors 收起 <<	Phase 1	Terminated(Sponsor decision)	-	United States, Maryland ... 展开 >> Site Reference ID/Investigator# 51465 Baltimore, Maryland, United States, 21231 United States, Michigan Site Reference ID/Investigator# 61282 Detroit, Michigan, United States, 48201 United States, New Hampshire Site Reference ID/Investigator# 51463 Lebanon, New Hampshire, United States, 03756-0001 United States, Texas Site Reference ID/Investigator# 52122 San Antonio, Texas, United States, 78229 收起 <<
NCT01381341	Advanced Solid Tumors	Phase 1	Completed	-	United States, Washington ... 展开 >> Site Reference ID/Investigator# 51403 Tacoma, Washington, United States, 98405 收起 <<
NCT00517920	Advanced Hepatocellular Carcin... 展开 >>oma 收起 <<	Phase 2	Completed	-	United States, Pennsylvania ... 展开 >> Site Reference ID/Investigator# 7726 Philadelphia, Pennsylvania, United States, 19107 Canada Site Reference ID/Investigator# 7169 Toronto, Canada, M5G 2M9 Site Reference ID/Investigator# 5837 Vancouver, Canada, V5Z 4E6 Singapore Site Reference ID/Investigator# 5235 Singapore, Singapore, 119228 Site Reference ID/Investigator# 5611 Singapore, Singapore, 169610 Taiwan Site Reference ID/Investigator# 6265 Taipei, Taiwan, 10002 收起 <<
NCT00754104	Solid Tumors	Phase 1	Withdrawn	-	-

利尼伐尼 /Linifanib {[allProObj[0].p_purity_real_show]}

Linifanib 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Linifanib 质控信息

Linifanib 生物活性

Linifanib 细胞研究

Linifanib 动物研究

Linifanib 临床研究

Linifanib 参考文献

Linifanib 实验方案

Linifanib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

VEGFR1	VEGFR1/FLT1, IC50:3 nM
VEGFR3	VEGFR3/FLT4, IC50:190 nM
VEGFR2	VEGFR2/KDR, IC50:4 nM
PDGFRβ	PDGFRβ, IC50:66 nM

利尼伐尼 /Linifanib {[allProObj[0].p_purity_real_show]}

Linifanib 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Linifanib 质控信息

Linifanib 生物活性

Linifanib 细胞研究

Linifanib 动物研究

Linifanib 临床研究

Linifanib 参考文献

Linifanib 实验方案

Linifanib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Linifanib 纯度/质量文件产品仅供科研